Antitrust Regulators Clear Biovail's Wellbutrin XL Deal With GSK

Fri, 05/15/2009 - 4:23am
NEW YORK (AP) — Biovail Corp. has acquired full U.S. rights to the antidepressant Wellbutrin XL after antitrust regulators finished reviewing Biovail's agreement to purchase them from GlaxoSmithKline PLC. Biovail paid $510 million for the rights to Wellbutrin XL, fulfilling an agreement the companies made last week. The Toronto-based company helped develop the drug, and although sales have fallen sharply since generic versions reached the market a year ago, Biovail plans to use its new revenue from Wellbutrin XL to help fund development or acquisition of other products.

Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.